PD‐1/PD‐L1 ICIs including Pembrolizumab [3, 4, 5, 6, 7], Nivolumab [8], Cemiplimab [9, 10], Atezolizumab [11, 12, 13, 14], and Durvalumab [15, 16] have received FDA approval for the treatment of unresectable locally advanced or metastatic nonsmall cell lung cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.